Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.35 USD | -.--% | +4.55% | -17.04% |
May. 29 | Transcript : Aura Biosciences, Inc. - Special Call | |
May. 09 | Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 496 | 388.9 | 436.4 | 364.1 | - | - |
Enterprise Value (EV) 1 | 496 | 388.9 | 436.4 | 364.1 | 364.1 | 364.1 |
P/E ratio | -10.7 x | -5.36 x | -4.59 x | -4.06 x | -3.71 x | -3.42 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -14.4 x | -6.45 x | - | -3.75 x | -3.31 x | -2.91 x |
FCF Yield | -6.96% | -15.5% | - | -26.6% | -30.2% | -34.3% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 29,211 | 37,040 | 49,260 | 49,543 | - | - |
Reference price 2 | 16.98 | 10.50 | 8.860 | 7.350 | 7.350 | 7.350 |
Announcement Date | 3/23/22 | 3/15/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -35.25 | -60.3 | -84.99 | -96.72 | -103.6 | -119 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -35.25 | -58.76 | -76.27 | -93.1 | -97.35 | -114.8 |
Net income 1 | -22.21 | -46.19 | -58.76 | -76.41 | -92.39 | -108.5 | -133.8 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -5.990 | -1.581 | -1.960 | -1.930 | -1.812 | -1.980 | -2.147 |
Free Cash Flow 1 | - | -34.54 | -60.3 | - | -97 | -110 | -125 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 10/8/21 | 3/23/22 | 3/15/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -11.63 | -12.81 | -13.82 | -16.06 | -17.61 | -19.44 | -20.28 | -20.49 | -24.78 | -22.31 | -23.8 | -24.74 | -25.9 | -25.1 | -25.9 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -11.63 | -12.84 | -13.47 | -15.9 | -16.56 | -17.47 | -18.3 | -18.51 | -21.99 | -19.66 | -22.3 | -23.2 | -24.95 | - | - |
Net income 1 | -12.95 | -12.84 | -13.47 | -15.9 | -16.56 | -17.47 | -18.3 | -18.51 | -22.13 | -19.71 | -22.68 | -24.23 | -25.8 | -23.64 | -24.6 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.6700 | -0.4400 | -0.4600 | -0.5400 | -0.5200 | -0.4600 | -0.4800 | -0.4800 | -0.5000 | -0.4000 | -0.4520 | -0.4800 | -0.4860 | -0.5050 | -0.5250 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/23/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/15/23 | 5/11/23 | 8/9/23 | 11/9/23 | 3/27/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -34.5 | -60.3 | - | -97 | -110 | -125 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 0.9 | 0.9 | 1 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 10/8/21 | 3/23/22 | 3/15/23 | 3/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.04% | 364M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- AURA Stock
- Financials Aura Biosciences, Inc.